Spinocerebellar Ataxia – Epidemiology – Mature Markets Data
Clarivate Epidemiology's coverage of spinocerebellar ataxia (SCA) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the diagnosed prevalence of SCA for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology's spinocerebellar ataxia forecast will answer the following questions:
Of all people with SCA, how many in each country across the mature pharmaceutical markets have been formally diagnosed?
Among all people with subtypes of SCA, how many in each country across the mature pharmaceutical markets have been formally diagnosed?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four SCA patient populations, as follows:
Diagnosed prevalent cases of spinocerebellar ataxia.
Diagnosed prevalent cases of spinocerebellar ataxia type 1.
Diagnosed prevalent cases of spinocerebellar ataxia type 2.
Diagnosed prevalent cases of spinocerebellar ataxia type 3.
Spinocerebellar Ataxiau00a0 - Epidemiology - Mature Markets Data
Diagnosed Prevalence of Spinocerebellar Ataxia per 100,000 People of All ages in 2021 and 2041
Diagnosed Prevalence by Disease subtype
Studies Included in the Analysis of Spinocerebellar Ataxia
Studies Excluded From the Analysis of Spinocerebellar Ataxia
Risk/Protective Factors for Spinocerebellar Ataxia
Utsav Patel, M.P.H.,is an associate epidemiologist at Clarivate. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
Alexandre Vo Dupuy, Pharm.D., M.Sc.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux.